Lercanidipina Jaba

Lercanidipine Hydrochloride, the active ingredient in Lercanidipina Jaba, is a calcium channel blocker presented as an oral tablet for oral use. It is indicated for the management of hypertension in adult patients and works by relaxing vascular smooth muscle, thereby lowering systemic vascular resistance.

GNH USA supplies Lercanidipina Jaba as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to Good Distribution Practice and provides regulatory documentation to support import and clinical use.

Lercanidipine Hydrochloride is used to treat conditions related to elevated arterial pressure.

- Hypertension: reduces high blood pressure, helping to prevent cardiovascular complications.

Lercanidipine Hydrochloride may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often occurring shortly after dosing. - Flushing: transient redness and warmth of the skin. - Peripheral edema: swelling of the lower limbs due to fluid accumulation. - Dizziness: sensation of light‑headedness, especially when standing quickly.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that may cause fainting. - Angioedema: rapid swelling of the face, lips, tongue, or throat requiring urgent care. - Myocardial infarction: rare occurrence of heart attack associated with abrupt blood pressure changes.

Before initiating therapy, clinicians should consider several safety factors. - Blood pressure monitoring: check baseline and periodic readings to assess response. - Avoid abrupt discontinuation: tapering may be needed to prevent rebound hypertension. - Hepatic impairment: use with caution in patients with liver dysfunction. - Elderly patients: start at lower doses due to increased sensitivity. - Concomitant CYP3A4 inhibitors: may raise drug levels, requiring dose adjustment. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Lercanidipine Hydrochloride can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Concurrent use with other antihypertensives: risk of excessive hypotension.

Moderate Interactions (Monitor Closely):\n- Grapefruit juice: can elevate drug exposure. - Diuretics: may enhance hypotensive response. - Beta‑blockers: additive blood pressure lowering may require dose titration.